Ammonia Predicts Hepatic Involvement and Pulmonary Hypertension in Patients With Hereditary Hemorrhagic Telangiectasia

Patricia P. Bloom,Josanna Rodriguez-Lopez,Alison S. Witkin,Hanny Al-Samkari,David J. Kuter,Amirkasra Mojtahed,Jay Luther
DOI: https://doi.org/10.14309/ctg.0000000000000118
2020-01-01
Clinical and Translational Gastroenterology
Abstract:Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant multisystem disorder characterized by vascular dysregulation, leading to telangiectasias and arteriovenous malformations (AVMs) of the skin, lung, gastrointestinal tract, liver, and brain. Although HHT is rare with a prevalence of approximately 1 in 5,000 people, hepatic involvement in the disease is common (<sup><a class="ejp-citation-link js-ejp-citation-link">1</a></sup>). The existing literature suggests that 32%–78% of patients with HHT have hepatic involvement, with AVMs affecting the destination of portal venous and hepatic arterial blood flow (<sup><a class="ejp-citation-link js-ejp-citation-link">1–3</a></sup>). The clinical consequences of hepatic AVMs include high-output cardiac failure, portal hypertension, ischemic biliary disease, hepatic encephalopathy, and abdominal angina (<sup><a class="ejp-citation-link js-ejp-citation-link">4</a></sup>). According to the largest longitudinal cohort study to date, approximately 25% of patients with hepatic HHT involvement eventually experience one of these complications (<sup><a class="ejp-citation-link js-ejp-citation-link">5</a></sup>).
gastroenterology & hepatology
What problem does this paper attempt to address?